These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33804240)

  • 1. The Glycolytic Pathway as a Target for Novel Onco-Immunology Therapies in Pancreatic Cancer.
    Curcio C; Brugiapaglia S; Bulfamante S; Follia L; Cappello P; Novelli F
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33804240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising Therapeutic Approach in Pancreatic Cancer: Metabolism-Related Genes.
    Choe S; Kwak W; Kim E; Shin S; Shin M; Koh HJ; Yoon H
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):137. PubMed ID: 38682209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment.
    Looi CK; Chung FF; Leong CO; Wong SF; Rosli R; Mai CW
    J Exp Clin Cancer Res; 2019 Apr; 38(1):162. PubMed ID: 30987642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VentX expression in tumor-associated macrophages promotes phagocytosis and immunity against pancreatic cancers.
    Le Y; Gao H; Richards W; Zhao L; Bleday R; Clancy T; Zhu Z
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging trends in the immunotherapy of pancreatic cancer.
    Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
    Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD147‑mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review).
    Li X; Xu W
    Oncol Rep; 2019 May; 41(5):2945-2956. PubMed ID: 30864716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactate in the tumour microenvironment: From immune modulation to therapy.
    Wang ZH; Peng WB; Zhang P; Yang XP; Zhou Q
    EBioMedicine; 2021 Nov; 73():103627. PubMed ID: 34656878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer.
    Rech AJ; Dada H; Kotzin JJ; Henao-Mejia J; Minn AJ; Twyman-Saint Victor C; Vonderheide RH
    Cancer Res; 2018 Aug; 78(15):4282-4291. PubMed ID: 29844122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.
    Jiang H; Courau T; Borison J; Ritchie AJ; Mayer AT; Krummel MF; Collisson EA
    Gastroenterology; 2022 Feb; 162(2):590-603.e14. PubMed ID: 34627860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of pancreatic cancer.
    Sunami Y; Kleeff J
    Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
    Blair AB; Zheng L
    Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
    Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
    Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell programming in pancreatic adenocarcinoma: a review.
    Seo YD; Pillarisetty VG
    Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
    Fu Y; Liu S; Zeng S; Shen H
    Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
    Torphy RJ; Schulick RD; Zhu Y
    Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease.
    Hutcheson J; Balaji U; Porembka MR; Wachsmann MB; McCue PA; Knudsen ES; Witkiewicz AK
    Clin Cancer Res; 2016 Jul; 22(14):3606-17. PubMed ID: 26858311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.
    Orozco CA; Martinez-Bosch N; Guerrero PE; Vinaixa J; Dalotto-Moreno T; Iglesias M; Moreno M; Djurec M; Poirier F; Gabius HJ; Fernandez-Zapico ME; Hwang RF; Guerra C; Rabinovich GA; Navarro P
    Proc Natl Acad Sci U S A; 2018 Apr; 115(16):E3769-E3778. PubMed ID: 29615514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ONECUT3 blocks glycolytic metabolism and potentiates anti-PD-1 therapy in pancreatic cancer.
    Chen PC; Ning Y; Li H; Su JG; Shen JB; Feng QC; Jiang SH; Shi PD; Guo RS
    Cell Oncol (Dordr); 2024 Feb; 47(1):81-96. PubMed ID: 37606818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.
    Yazdanifar M; Zhou R; Grover P; Williams C; Bose M; Moore LJ; Wu ST; Maher J; Dreau D; Mukherjee AP
    Cells; 2019 Sep; 8(9):. PubMed ID: 31514488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.